



VACCINES PRODUCED IN 2003-4 FOR THE MINISTRY OF HEALTH

	BUTANTAN	OTHERS
PRODUCED	483,000,000 86%	79,000,000
FROM BULK	46,500,000 12%	319,200,000
TOTAL	529,500,000 57%	398,200,000

H5N1 PILOT

- GMP LAB 500 M2 FOR PRODUCTION IN EGGS
- TRIAL WITH/WITHOUT ADJUVANTS
- TRIAL INTRADERMAL



ANTIGEN SPARING PROGRAM

- 1. ALUMINUM HYDROXIDE**
- 2. ALUMINUM HYDROXIDE+ MPLA**
- 3. LUNG SURFACTANT**
- 4. INTRADERMAL ROUTE**

ATIVIDADE IMUNOGÊNICA VACINA CONTRA INFLUENZA

ADSORVIDA COM GEL DE HIDROXIDO DE ALUMINIO

FORMULAÇÃO COM CEPAS	DILUIÇÃO	1/1	1/4	1/10	1/25
	A/Wyoming				
Sem Adjuvante		160	160	80	80
Com Al (OH) ₃		640	320	80	80
A/New Caledonia					
Sem Adjuvante		80	40	40	40
Com Al (OH) ₃		160	160	80	80
B/Shangdong					
Sem Adjuvante		160	80	80	40
Com Al (OH) ₃		320	160	160	160

CAMUNDONGOS – 30 DIAS

ATIVIDADE IMUNOGÊNICA VACINA CONTRA INFLUENZA

FORMULAÇÃO COM CEPAS	Al (OH) ₃ 0,5mg/dose	MPLA 0,2 nmg/dose	VIA INTRA- DERMICA SEM ADJUVANTE	VIA INTRA- PERITONIAL SEM ADJUVANTE
A/Wyoming	1/640	1/640	1/80	1/80
A/New Caledonia	1/640	1/640	1/80	1/160
B/Shangdong	1/1280	1/1280	1/80	1/80

COBAIAS – 30 DIAS

Human volunteers 4 mmg im with alum

	H1N1	H3N2	B
<40	16	6	49
40-160	27	32	10
> 320	17	22	1